MedTrace Logo

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

NCT06380660 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 298

Last updated 2025-12-29

No results posted yet for this study

Summary

The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

Conditions

Interventions

DRUG

ACE-86225106 tablet

ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.

Sponsors & Collaborators

  • Acerand Therapeutics (Shanghai) Limited

    lead INDUSTRY

Principal Investigators

  • Sherwin Cai, MD · Acerand Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-22
Primary Completion
2028-12-21
Completion
2029-03-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06380660 on ClinicalTrials.gov